Cookies?
Library Header Image
LSE Research Online LSE Library Services

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

Davis, Courtney and Naci, Huseyin and Gurpinar, Evrim and Poplavska, Elita and Pinto, Ashlyn and Aggarwal, Ajay (2017) Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ (359). ISSN 1756-1833

[img]
Preview
Text - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Identification Number: 10.1136/bmj.j4530

Abstract

Objective To determine the availability of data on overall survival and quality of life benefits of cancer drugs approved in Europe. Design Retrospective cohort study. Setting Publicly accessible regulatory and scientific reports on cancer approvals by the European Medicines Agency (EMA) from 2009 to 2013. Main outcome measures Pivotal and postmarketing trials of cancer drugs according to their design features (randomisation, crossover, blinding), comparators, and endpoints. Availability and magnitude of benefit on overall survival or quality of life determined at time of approval and after market entry. Validated European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) used to assess the clinical value of the reported gains in published studies of cancer drugs. Results From 2009 to 2013, the EMA approved the use of 48 cancer drugs for 68 indications. Of these, eight indications (12%) were approved on the basis of a single arm study. At the time of market approval, there was significant prolongation of survival in 24 of the 68 (35%). The magnitude of the benefit on overall survival ranged from 1.0 to 5.8 months (median 2.7 months). At the time of market approval, there was an improvement in quality of life in seven of 68 indications (10%). Out of 44 indications for which there was no evidence of a survival gain at the time of market authorisation, in the subsequent postmarketing period there was evidence for extension of life in three (7%) and reported benefit on quality of life in five (11%). Of the 68 cancer indications with EMA approval, and with a median of 5.4 years’ follow-up (minimum 3.3 years, maximum 8.1 years), only 35 (51%) had shown a significant improvement

Item Type: Article
Official URL: http://www.bmj.com/
Additional Information: © 2017 The Authors © CC-BY-NC 4.0
Subjects: R Medicine > R Medicine (General)
Sets: Departments > Health Policy
Date Deposited: 12 Oct 2017 09:38
Last Modified: 10 Nov 2017 14:56
URI: http://eprints.lse.ac.uk/id/eprint/84606

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics